News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
229,135 Results
Type
Article (7354)
Company Profile (18)
Press Release (221763)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (63385)
Career Advice (294)
Deals (14806)
Drug Delivery (28)
Drug Development (37036)
Employer Resources (24)
FDA (6475)
Job Trends (4945)
News (122384)
Policy (11725)
Tag
2024 BioMidwest Digital (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (1)
2024 Lone Star Bio Digital (1)
Academia (573)
Accelerated approval (2)
Adcomms (7)
Allergies (35)
Alliances (14869)
ALS (28)
Alzheimer's disease (601)
Antibody-drug conjugate (ADC) (40)
Approvals (6520)
Artificial intelligence (102)
Autoimmune disease (10)
Automation (3)
Bankruptcy (147)
Best Places to Work (4645)
BIOSECURE Act (2)
Biosimilars (21)
Biotechnology (20)
Bladder cancer (49)
Brain cancer (14)
Breast cancer (107)
Cancer (1153)
Cardiovascular disease (70)
Career advice (258)
Career pathing (4)
CAR-T (90)
Cell therapy (217)
Cervical cancer (12)
Clinical research (31355)
Collaboration (306)
Compensation (89)
Complete response letters (8)
COVID-19 (724)
CRISPR (18)
C-suite (75)
Cystic fibrosis (37)
Data (1285)
Denatured (1)
Depression (19)
Diabetes (109)
Diagnostics (2247)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (49)
Drug pricing (41)
Drug shortages (17)
Duchenne muscular dystrophy (55)
Earnings (33392)
Editorial (14)
Employer branding (1)
Employer resources (19)
Events (31236)
Executive appointments (249)
FDA (7146)
Featured Employer (4)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (270)
Gene editing (47)
Generative AI (10)
Gene therapy (131)
GLP-1 (187)
Government (1272)
Grass and pollen (2)
Guidances (35)
Healthcare (6161)
Huntington's disease (11)
IgA nephropathy (14)
Immunology and inflammation (36)
Indications (17)
Infectious disease (786)
Inflammatory bowel disease (58)
Inflation Reduction Act (5)
Influenza (24)
Intellectual property (51)
Interviews (45)
IPO (8047)
IRA (17)
Job creations (573)
Job search strategy (221)
Kidney cancer (8)
Labor market (5)
Layoffs (43)
Leadership (3)
Legal (2106)
Liver cancer (38)
Lung cancer (184)
Lymphoma (82)
Machine learning (1)
Management (7)
Manufacturing (105)
MASH (37)
Medical device (4586)
Medtech (4587)
Mergers & acquisitions (7112)
Metabolic disorders (279)
Multiple sclerosis (38)
NASH (8)
Neurodegenerative disease (27)
Neuropsychiatric disorders (4)
Neuroscience (812)
NextGen: Class of 2025 (1515)
Non-profit (723)
Northern California (1270)
Obesity (138)
Opinion (75)
Ovarian cancer (53)
Pain (35)
Pancreatic cancer (46)
Parkinson's disease (66)
Partnered (5)
Patents (133)
Patient recruitment (62)
Peanut (17)
People (14578)
Pharmaceutical (8)
Pharmacy benefit managers (6)
Phase I (10035)
Phase II (13815)
Phase III (10347)
Pipeline (732)
Policy (32)
Postmarket research (799)
Preclinical (3654)
Press Release (10)
Prostate cancer (50)
Psychedelics (11)
Radiopharmaceuticals (118)
Rare diseases (163)
Real estate (1008)
Recruiting (7)
Regulatory (9237)
Reports (13)
Research institute (513)
Resumes & cover letters (39)
Rett syndrome (3)
RNA editing (2)
RSV (16)
Schizophrenia (26)
Series A (44)
Series B (30)
Service/supplier (2)
Sickle cell disease (28)
Southern California (1112)
Special edition (2)
Spinal muscular atrophy (33)
Sponsored (14)
Startups (681)
Stomach cancer (5)
Supply chain (25)
Tariffs (3)
The Weekly (1)
United States (10611)
Vaccines (168)
Venture capitalists (5)
Weight loss (76)
Women's health (6)
Worklife (4)
Date
Today (66)
Last 7 days (266)
Last 30 days (1181)
Last 365 days (15938)
2025 (4618)
2024 (17047)
2023 (19228)
2022 (22380)
2021 (23754)
2020 (21885)
2019 (14525)
2018 (10687)
2017 (11507)
2016 (9619)
2015 (11811)
2014 (8140)
2013 (5899)
2012 (6070)
2011 (6785)
2010 (6257)
Location
Africa (176)
Alabama (16)
Alaska (2)
Arizona (54)
Arkansas (3)
Asia (17635)
Australia (4852)
California (2871)
Canada (1116)
China (246)
Colorado (125)
Connecticut (161)
Delaware (58)
Europe (28177)
Florida (421)
Georgia (68)
Idaho (6)
Illinois (206)
India (20)
Indiana (123)
Japan (90)
Kansas (14)
Kentucky (6)
Louisiana (5)
Maine (36)
Maryland (356)
Massachusetts (2066)
Michigan (51)
Minnesota (102)
Missouri (36)
Montana (11)
Nebraska (8)
Nevada (39)
New Hampshire (36)
New Jersey (999)
New Mexico (3)
New York (909)
North Carolina (392)
North Dakota (2)
Northern California (1270)
Ohio (62)
Oklahoma (1)
Oregon (7)
Pennsylvania (669)
Puerto Rico (6)
Rhode Island (8)
South America (303)
South Carolina (11)
Southern California (1112)
Tennessee (42)
Texas (430)
Utah (67)
Virginia (76)
Washington D.C. (17)
Washington State (343)
West Virginia (2)
Wisconsin (11)
229,135 Results for "exonate limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys 51 in a patient population amenable to exon 51 skipping.
March 17, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II FORWARD-53 trial. Wave plans to file for accelerated approval of the candidate in 2026.
March 26, 2025
·
3 min read
·
Heather McKenzie
Business
Exonate Appoints Dr Rafiq Hasan as Non-Executive Director
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director.
May 28, 2024
·
2 min read
Press Releases
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
April 24, 2025
·
6 min read
Business
Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies
Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.
June 18, 2024
·
2 min read
·
Tyler Patchen
Business
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
June 18, 2024
·
3 min read
Press Releases
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
January 13, 2025
·
11 min read
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Press Releases
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
January 14, 2025
·
6 min read
Press Releases
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
March 25, 2025
·
7 min read
1 of 22,914
Next
